Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pf-00446687. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R known ✓ | P32245 | 20/20 | 1.00 |
| ▸ | MC5R | P33032 | 8/20 | 0.98 |
| ▸ | MC3R | P41968 | 7/20 | 0.98 |
| ▸ | MC1R | Q01726 | 5/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pf-00446687 SCHEMBL13525566 | 1.00 | MC4R (1.00) | MC4RMC5RMC3RMC1RKCNH2 | |
| Pf-00446687 SCHEMBL31737754 | 1.00 | MC4R (1.00) | MC4RMC5RMC3RMC1RKCNH2 | |
| Pf-00446687 SCHEMBL1921717 | 1.00 | MC4R (1.00) | MC4RMC5RMC3RMC1RKCNH2 | |
| Pf-00446687 SCHEMBL13525576 | 1.00 | MC4R (1.00) | MC4RMC5RMC3RMC1RKCNH2 | |
| Pf-00446687 SCHEMBL1920461 | 1.00 | MC4R (1.00) | MC4RMC5RMC3RMC1RKCNH2 | |
| Pf-00446687 SCHEMBL3161207 | 1.00 | MC4R (1.00) | MC4RMC5RMC3RMC1RKCNH2 | |
| Pf-00446687 SCHEMBL1922168 | 0.99 | MC4R (1.00) | MC4RMC5RMC3RMC1RKCNH2 | |
| Pf-00446687 SCHEMBL1921070 | 0.99 | MC4R (1.00) | MC4RMC5RMC3RMC1RKCNH2 | |
| Pf-00446687 SCHEMBL1920692 | 0.99 | MC4R (1.00) | MC4RMC5RMC3RMC1RKCNH2 | |
| SCHEMBL12533598 | 0.94 | MC4R (1.00) | MC4RMC5RMC3RMC1RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1716135-B1 | PIPERIDINYLCARBONYL-PYRROLIDINES AND THEIR USE AS MELANOCORTIN AGONISTS | PFIZER LTD (GB) | 2011-06-01 | — | — | EP | claimed |
| US-7649002-B2 | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists | PFIZER INC (US) | 2010-01-19 | — | — | US | claimed |
| US-20080234280-A1 | Use of Mc4 Receptor Agonist Compounds | MCMURRAY GORDON | 2008-09-25 | — | — | US | claimed |
| EP-1716135-A1 | PIPERIDINYLCARBONYL-PYRROLIDINES AND THEIR USE AS MELANOCORTIN AGONISTS | Pfizer Limited (GB) | 2006-11-02 | — | — | EP | claimed |
| WO-2005077935-A1 | PIPERIDINYLCARBONYL-PYRROLIDINES AND THEIR USE AS MELANOCORTIN AGONISTS | PFIZER LIMITED (GB) | 2005-08-25 | — | — | WO | claimed |
| US-20050176772-A1 | Pharmaceutically active compounds | PFIZER INC | 2005-08-11 | — | — | US | claimed |
| WO-2024108198-A2 | METHODS OF TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-1716135-B1 | PIPERIDINYLCARBONYL-PYRROLIDINES AND THEIR USE AS MELANOCORTIN AGONISTS | PFIZER LTD (GB) | 2011-06-01 | — | — | EP | disclosed |
| US-7649002-B2 | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists | PFIZER INC (US) | 2010-01-19 | — | — | US | disclosed |
| US-20080234280-A1 | Use of Mc4 Receptor Agonist Compounds | MCMURRAY GORDON | 2008-09-25 | — | — | US | disclosed |
| EP-1928460-A2 | MC4R-AGONISTS FOR THE TREATMENT OF URINARY TRACT DYSFUNCTION | Pfizer Limited (GB) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007015157-A2 | MC4R-AG0NISTS FOR THE TREATMENT OF URINARY TRACT DYSFUNCTION | PFIZER LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
| EP-1716135-A1 | PIPERIDINYLCARBONYL-PYRROLIDINES AND THEIR USE AS MELANOCORTIN AGONISTS | Pfizer Limited (GB) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005077935-A1 | PIPERIDINYLCARBONYL-PYRROLIDINES AND THEIR USE AS MELANOCORTIN AGONISTS | PFIZER LIMITED (GB) | 2005-08-25 | — | — | WO | disclosed |
| US-20050176772-A1 | Pharmaceutically active compounds | PFIZER INC | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176772-A1 | Pharmaceutically active compounds | MC4R, MC3R, MC5R | MC4R 1/4885MC5R 3/4885MC3R 2/4885 |
| US-20080234280-A1 | Use of Mc4 Receptor Agonist Compounds | MC4R, MC5R, GPR4 | MC4R 1/4885MC5R 2/4885MC3R 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.